INTERNATIONAL PATENT: AC IMMUNE SA FILES APPLICATION FOR "IMIDAZO[1,2-D][1,2,4]TRIAZINE DERIVATIVES FOR USE AS INHIBITORS OF THE NLRP3 INFLAMMASOME PATHWAY"

GENEVA, July 29 -- AC IMMUNE SA (EPFL Innovation Park, Building B1015 Lausanne) filed a patent application (PCT/EP2025/051050) for "IMIDAZO[1,2-D][1,2,4]TRIAZINE DERIVATIVES FOR USE AS INHIBITORS OF THE NLRP3 INFLAMMASOME PATHWAY" on Jan 16, 2025. With publication no. WO/2025/153625, the details related to the patent application was published on Jul 24, 2025.

Notably, the patent application was submitted under the International Patent Classification (IPC) system, which is managed by the World Intellectual Property Organization (WIPO).

Inventor(s): MOLETTE, Jerome (EPFL Innovation Park, Building B1015 Lausanne)

Abstract: The present invention relates to novel compounds for the treatment, alleviation or prevention of a group of diseases,...